Raymond James Financial Services Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,821	Closed	-$161K	–	3315
2021 Q1	$161K	Buy	+15,821	New	+$163K	﹤0.01%	2953
2020 Q4	–	Sell	-12,703	Closed	-$44K	–	2997
2020 Q3	$44K	Buy	+12,703	New	+$54.4K	﹤0.01%	2780
2019 Q1	–	Sell	-28,703	Closed	-$232K	–	2803
2018 Q4	$232K	Buy	+28,703	New	+$223K	﹤0.01%	2162
2016 Q4	–	Sell	-12,883	Closed	-$57K	–	2350
2016 Q3	$57K	Sell	12,883 -8,200	-39%	-$32.8K	﹤0.01%	2198
2016 Q2	$60K	Buy	21,083 +7,100	+51%	+$22K	﹤0.01%	2162
2016 Q1	$40K	Buy	+13,983	New	+$62K	﹤0.01%	1981

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Raymond James Financial Services Advisors's BCRX Position: Q2 2021 in Review

Raymond James Financial Services Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 15,821 shares — an estimated $161K sold.

Raymond James Financial Services Advisors first reported a position in BCRX in Q1 2016 and held it in 6 quarters. The position peaked at $232K in Q4 2018. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

Raymond James Financial Services Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Raymond James Financial Services Advisors sold 15,821 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $161K.
Raymond James Financial Services Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 6 quarters.
Raymond James Financial Services Advisors's BioCryst Pharmaceuticals position peaked at $232K in Q4 2018.
195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.